J&J re­ports sec­ond HIV vac­cine reg­i­men fail­ure in 18 months

Af­ter more than four decades, there is still no ap­proved HIV vac­cine. And an­oth­er so-called mo­sa­ic reg­i­men has end­ed in dis­ap­point­ment.

John­son & John­son’s Janssen unit said Wednes­day that an in­de­pen­dent da­ta and safe­ty mon­i­tor­ing team found the Big Phar­ma’s reg­i­men to be in­ef­fec­tive at pre­vent­ing HIV in­fec­tion com­pared to place­bo. The drug de­vel­op­er re­port­ed no safe­ty is­sues.

With that, J&J end­ed the Phase III Mo­saico study, which en­rolled 3,900 cis­gen­der men and trans­gen­der in­di­vid­u­als in Ar­genti­na, Brazil, Italy, Mex­i­co, Pe­ru, Poland, Puer­to Ri­co, Spain and the US. Peo­ple in the tri­al who con­tract­ed the virus were giv­en “prompt HIV treat­ment and care,” the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER